
|Articles|March 22, 2004
New biologic offers hope as first-line colorectal cancer agent
The FDA recently approved bevacizumab (Avastin, Genentech) for use in combination with intravenous 5-fluorouracil-based chemotherapy for the first-line treatment of metastatic CRC. Bevacizumab is the first angiogenesis inhibitor to be approved for use in the U.S. Genentech began to ship bevacizumab to wholesalers within 3 days of its approval.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Eli Lilly, Walmart Announce Expansion of Direct-to Consumer Access for Tirzepatide
2
White House Announces Action to Increase Competition, Decrease Cost of Biosimilar Development
3
FDA Approves Mirikizumab as Once Monthly Injection for Moderately to Severely Active Ulcerative Colitis
4
American Pharmacists Month: Clinical Service Expansion Benefits Patient Outcomes, Pharmacist Profession
5


























































































































































